{
    "clinical_study": {
        "@rank": "126208", 
        "acronym": "LESO", 
        "arm_group": [
            {
                "arm_group_label": "tDCS + SSRI", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "tDCS + placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "sham-tDCS + SSRI", 
                "arm_group_type": "Sham Comparator"
            }, 
            {
                "arm_group_label": "sham-DCS + placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to assess whether the application of a selective serotonin reuptake\n      inhibitor (SSRI) enhances and prolongs the learning enhancement achieved by anodal\n      transcranial direct current stimulation (atDCS). For this, young and older healthy subjects\n      will be tested with a well established learning paradigm. Results of this study may help to\n      support the application of atDCS also in patients, e.g. with dementia or mild cognitive\n      impairment."
        }, 
        "brief_title": "Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin", 
        "condition": "Healthy Young and Older Adults", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  right handedness\n\n          -  unobtrusive neuropsychological screening\n\n          -  ability to provide written informed consent\n\n          -  no pathological findings in head MRI\n\n          -  age: 18 to 35 years (young adults) or 50-80 years (older adults)\n\n          -  Highly effective contraception (Pearl Index < 1) or reliable abstinence from any\n             heterosexual relationships in women of childbearing potential\n\n        Exclusion Criteria:\n\n          -  severe internal or psychiatric disease (especially depression or suicidal thoughts)\n\n          -  epilepsy\n\n          -  cognitive impairment (< SD under age adjusted norm in neuropsychological testing)\n\n          -  concurrent taking of serotonin precursors (tryptophan, 5-HTP) or MAO inhibitors\n\n          -  concurrent taking of tramadol or triptans\n\n          -  concurrent taking of pimozide or linezolid\n\n          -  concurrent taking of other drugs prolonging the QT-interval\n\n          -  long-QT-syndrome\n\n          -  hypokalemia or hypomagnesemia\n\n          -  known intolerance of the study medication\n\n          -  claustrophobia or metallic implants, tattoos (MRI exclusion criteria)\n\n          -  pregnancy or lactation\n\n          -  participation in another drug-interventional clinical trial within the last month or\n             during the entire study\n\n          -  probands that are placed in an institution due to official or judicial order\n\n          -  non-agreement to save and transmit pseudonymised study data within the clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092974", 
            "org_study_id": "LESO"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "tDCS + SSRI", 
                    "tDCS + placebo"
                ], 
                "intervention_name": "tDCS", 
                "intervention_type": "Procedure", 
                "other_name": "transcranial direct current stimulation"
            }, 
            {
                "arm_group_label": [
                    "tDCS + SSRI", 
                    "sham-tDCS + SSRI"
                ], 
                "intervention_name": "Citalopram", 
                "intervention_type": "Drug", 
                "other_name": "SSRI"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Citalopram", 
                "Serotonin Uptake Inhibitors", 
                "Dexetimide", 
                "Serotonin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "transcranial direct current stimulation (tDCS)", 
            "selective serotonin reuptake inhibitor (SSRI)", 
            "young", 
            "older adults"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "contact": {
                "email": "agnes.floeel@charite.de", 
                "last_name": "Agnes Fl\u00f6el, Prof. Dr.", 
                "phone": "0049 30 450560284"
            }, 
            "contact_backup": {
                "email": "kristin.prehn@charite.de", 
                "last_name": "Kristin Prehn, Dr.", 
                "phone": "0049 30 450560140"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10117"
                }, 
                "name": "Charite Universit\u00e4tsmedizin Berlin"
            }, 
            "investigator": {
                "last_name": "Agnes Fl\u00f6el, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin", 
        "overall_contact": {
            "email": "agnes.floeel@charite.de", 
            "last_name": "Agnes Fl\u00f6el, Prof. Dr.", 
            "phone": "0049 30 450 560284"
        }, 
        "overall_contact_backup": {
            "email": "kristin.prehn@charite.de", 
            "last_name": "Kristin Prehn, Dr.", 
            "phone": "0049 30 450 560140"
        }, 
        "overall_official": {
            "affiliation": "Charite University, Berlin, Germany", 
            "last_name": "Agnes Fl\u00f6el, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Recall score immediately after learning phase (=training of visual-spatial abilities) under tDC stimulation + SSRI application compared to learning under tDC stimulation + placebo.", 
            "measure": "Recall score after learning under tDC stimulation + SSRI compared to learning under tDC stimulation + placebo.", 
            "safety_issue": "No", 
            "time_frame": "immediately after end of learning phase (approx. 1 hour)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092974"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Charite University, Berlin, Germany", 
            "investigator_full_name": "Agnes Fl\u00f6el", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Measurement of recall scores on the evening of the same day after the learning phase (+tDCS + SSRI), the morning of the day after and 1 week later in order to assess the prolongation of atDCS induced learning enhancement by the SSRI.", 
                "measure": "prolongation of the atDCS induced learning enhancement by SSRI", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Measurement of recall scores directly after learning phase after application of atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo.", 
                "measure": "Increase of learning enhancement by atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo", 
                "safety_issue": "No", 
                "time_frame": "immediately after learning phase (approx. 1 hour)"
            }, 
            {
                "description": "Measurement of recall scores on the evening of the same day of learning phase, the morning of the day after and 1 week later under application of atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo, in order to assess prolongation of learning enhancement by SSRI.", 
                "measure": "prolongation of learning enhancement by atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "description": "To assess predictors of SSRI-enhanced brain stimulation, genotyping of several learning related polymorphisms will be performed (i.e., APOE, BDNF, Val66Met, COMT, Val158Met, KIBRA, rs17070145, 5-Hydroxytryptamine transporter).", 
                "measure": "genotyping of learning related polymorphisms", 
                "safety_issue": "No", 
                "time_frame": "once"
            }
        ], 
        "source": "Charite University, Berlin, Germany", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Charite University, Berlin, Germany", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}